Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 11;10(8):1948.
doi: 10.3390/biomedicines10081948.

Plant-Derived Bioactive Compounds in Colorectal Cancer: Insights from Combined Regimens with Conventional Chemotherapy to Overcome Drug-Resistance

Laura Ioana Gavrilas  1 , Daniel Cruceriu  2   3 , Andrei Mocan  4 , Felicia Loghin  5 , Doina Miere  1 , Ovidiu Balacescu  2
Affiliations
Review

Plant-Derived Bioactive Compounds in Colorectal Cancer: Insights from Combined Regimens with Conventional Chemotherapy to Overcome Drug-Resistance

Laura Ioana Gavrilas et al. Biomedicines. .

Abstract

Acquired drug resistance represents a major clinical problem and one of the biggest limitations of chemotherapeutic regimens in colorectal cancer. Combination regimens using standard chemotherapeutic agents, together with bioactive natural compounds derived from diet or plants, may be one of the most valuable strategies to overcome drug resistance and re-sensitize chemoresistant cells. In this review, we highlight the effect of combined regimens based on conventional chemotherapeutics in conjunction with well-tolerated plant-derived bioactive compounds, mainly curcumin, resveratrol, and EGCG, with emphasis on the molecular mechanisms associated with the acquired drug resistance.

Keywords: chemotherapy resistance; colorectal cancer; combination therapy; curcumin; drug resistance; epigallocatechin gallate; resveratrol.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Combinatory therapeutic strategies involving a systemic chemotherapeutic drug and a plant-derived compound that proved their efficiency in reversing the acquired drug resistance in CRC. OXA—oxaliplatin; 5-FU—5-fluorouracil; IRI—irinotecan: DOXO—doxorubicin; CURC—curcumin; EGCG—epigallocatechin gallate; RES—resveratrol; ↓—increased, ↑—decreased.
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Gelibter A.J., Caponnetto S., Urbano F., Emiliani A., Scagnoli S., Sirgiovanni G., Napoli V.M., Cortesi E. Adjuvant Chemotherapy in Resected Colon Cancer: When, How and How Long? Surg. Oncol. 2019;30:100–107. doi: 10.1016/j.suronc.2019.06.003. - DOI - PubMed
    1. Van der Stok E.P., Verhoef C., Grunhagen D.J. Neo-Adjuvant Chemotherapy Followed by Surgery versus Surgery Alone in High-Risk Patients with Resectable Colorectal Liver Metastases: The CHARISMA Randomized Multicenter Clinical Trial. J. Clin. Oncol. 2016;34:TPS790. doi: 10.1200/jco.2016.34.4_suppl.tps790. - DOI - PMC - PubMed
    1. Skarkova V., Kralova V., Vitovcova B., Rudolf E. Selected Aspects of Chemoresistance Mechanisms in Colorectal Carcinoma—A Focus on Epithelial-to-Mesenchymal Transition, Autophagy, and Apoptosis. Cells. 2019;8:234. doi: 10.3390/cells8030234. - DOI - PMC - PubMed
    1. Muniraj N., Siddharth S., Sharma D. Bioactive Compounds: Multi-Targeting Silver Bullets for Preventing and Treating Breast Cancer. Cancers. 2019;11:1563. doi: 10.3390/cancers11101563. - DOI - PMC - PubMed

LinkOut - more resources